Literature DB >> 11021803

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor.

L Hong1, G Koelsch, X Lin, S Wu, S Terzyan, A K Ghosh, X C Zhang, J Tang.   

Abstract

Memapsin 2 (beta-secretase) is a membrane-associated aspartic protease involved in the production of beta-amyloid peptide in Alzheimer's disease and is a major target for drug design. We determined the crystal structure of the protease domain of human memapsin 2 complexed to an eight-residue inhibitor at 1.9 angstrom resolution. The active site of memapsin 2 is more open and less hydrophobic than that of other human aspartic proteases. The subsite locations from S4 to S2' are well defined. A kink of the inhibitor chain at P2' and the change of chain direction of P3' and P4' may be mimicked to provide inhibitor selectivity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11021803     DOI: 10.1126/science.290.5489.150

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  133 in total

1.  Analysis of crystal structures of aspartic proteinases: on the role of amino acid residues adjacent to the catalytic site of pepsin-like enzymes.

Authors:  N S Andreeva; L D Rumsh
Journal:  Protein Sci       Date:  2001-12       Impact factor: 6.725

Review 2.  Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease.

Authors:  C Dingwall
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

3.  Backbone resonance assignments of the 45.3 kDa catalytic domain of human BACE1.

Authors:  Dingjiang Liu; Yu-Sen Wang; Jennifer J Gesell; Eileen Wilson; Brian M Beyer; Daniel F Wyss
Journal:  J Biomol NMR       Date:  2004-07       Impact factor: 2.835

Review 4.  Membrane proteases in the bacterial protein secretion and quality control pathway.

Authors:  Ross E Dalbey; Peng Wang; Jan Maarten van Dijl
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 5.  Inhibition of BACE1 for therapeutic use in Alzheimer's disease.

Authors:  Xiaoyang Luo; Riqiang Yan
Journal:  Int J Clin Exp Pathol       Date:  2010-07-08

6.  Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example.

Authors:  Lívia Barros Salum; Napoleão Fonseca Valadares
Journal:  J Comput Aided Mol Des       Date:  2010-07-27       Impact factor: 3.686

7.  In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors.

Authors:  Ting Yang; Dilyara Arslanova; Xiaoyin Xu; Yue-Ming Li; Weiming Xia
Journal:  J Neurochem       Date:  2010-03-12       Impact factor: 5.372

8.  Inhibition of beta-secretase in vivo via antibody binding to unique loops (D and F) of BACE1.

Authors:  Lujia Zhou; Lucia Chávez-Gutiérrez; Katrijn Bockstael; Ragna Sannerud; Wim Annaert; Patrick C May; Eric Karran; Bart De Strooper
Journal:  J Biol Chem       Date:  2011-01-05       Impact factor: 5.157

9.  Assigning the protonation states of the key aspartates in β-Secretase using QM/MM X-ray structure refinement.

Authors:  Ning Yu; Seth A Hayik; Bing Wang; Ning Liao; Charles H Reynolds; Kenneth M Merz
Journal:  J Chem Theory Comput       Date:  2006       Impact factor: 6.006

Review 10.  Targeting the β secretase BACE1 for Alzheimer's disease therapy.

Authors:  Riqiang Yan; Robert Vassar
Journal:  Lancet Neurol       Date:  2014-02-17       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.